ATE281838T1 - Anti-virales reagens - Google Patents

Anti-virales reagens

Info

Publication number
ATE281838T1
ATE281838T1 AT01110873T AT01110873T ATE281838T1 AT E281838 T1 ATE281838 T1 AT E281838T1 AT 01110873 T AT01110873 T AT 01110873T AT 01110873 T AT01110873 T AT 01110873T AT E281838 T1 ATE281838 T1 AT E281838T1
Authority
AT
Austria
Prior art keywords
present
virus agent
virus
construct
gene encoding
Prior art date
Application number
AT01110873T
Other languages
English (en)
Inventor
Marina N Papuashvili
Original Assignee
Technologie Integrale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technologie Integrale Ltd filed Critical Technologie Integrale Ltd
Application granted granted Critical
Publication of ATE281838T1 publication Critical patent/ATE281838T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT01110873T 2001-05-04 2001-05-04 Anti-virales reagens ATE281838T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/848,269 US20030176372A1 (en) 2001-05-04 2001-05-04 Anti-virus agent
EP01110873A EP1254663B1 (de) 2001-05-04 2001-05-04 Anti-virales Reagens

Publications (1)

Publication Number Publication Date
ATE281838T1 true ATE281838T1 (de) 2004-11-15

Family

ID=46679311

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01110873T ATE281838T1 (de) 2001-05-04 2001-05-04 Anti-virales reagens

Country Status (15)

Country Link
US (1) US20030176372A1 (de)
EP (1) EP1254663B1 (de)
JP (1) JP2005510455A (de)
CN (1) CN1527716A (de)
AT (1) ATE281838T1 (de)
CA (1) CA2446204A1 (de)
CZ (1) CZ20033288A3 (de)
DE (1) DE60107052T2 (de)
DK (1) DK1254663T3 (de)
ES (1) ES2234730T3 (de)
HU (1) HUP0400987A3 (de)
IL (1) IL158739A0 (de)
PL (1) PL367451A1 (de)
PT (1) PT1254663E (de)
WO (1) WO2002089817A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137415A1 (en) * 2007-04-20 2010-06-03 Takara Bio Inc. Vector for gene therapy
JP6915870B2 (ja) * 2016-01-27 2021-08-04 国立大学法人北海道大学 ウイルスフリー植物体の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973507A (en) * 1989-01-23 1990-11-27 Horian Richard C Thin wood laminate panel and method of fabrication
EP0479180A3 (en) * 1990-10-05 1992-08-26 Hoechst Aktiengesellschaft Virus resistant plants, method for their production

Also Published As

Publication number Publication date
DE60107052T2 (de) 2005-11-24
PL367451A1 (en) 2005-02-21
IL158739A0 (en) 2004-05-12
WO2002089817A3 (en) 2003-01-30
HUP0400987A2 (hu) 2004-08-30
EP1254663B1 (de) 2004-11-10
CN1527716A (zh) 2004-09-08
DE60107052D1 (de) 2004-12-16
CA2446204A1 (en) 2002-11-14
DK1254663T3 (da) 2005-03-21
ES2234730T3 (es) 2005-07-01
EP1254663A1 (de) 2002-11-06
HUP0400987A3 (en) 2004-10-28
CZ20033288A3 (cs) 2004-04-14
US20030176372A1 (en) 2003-09-18
JP2005510455A (ja) 2005-04-21
PT1254663E (pt) 2005-04-29
WO2002089817A2 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
EA200701450A1 (ru) РНКi МОДУЛЯЦИЯ RSV И ЕЁ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
FR21C1037I1 (fr) Clades de virus adéno associés (aav), séquences, vecteurs les contenant et leurs utilisations
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
DK1857122T3 (da) Stabiliseret mRNA med forøget G/C-indhold, kodende for et viralt antigen
DE69837708D1 (de) Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
MXPA03000061A (es) Manipulacion de virus de arn encadenados negativos mediante redisposicion de sus genes y usos de los mismos.
WO2005013905A3 (en) SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION
ATE294866T1 (de) Zellen, die virus-resistent und von viren infizierbar sind
ATE281838T1 (de) Anti-virales reagens
WO1999058639A3 (en) Structural proteins of fish pancreatic disease virus and uses thereof
WO2010014248A3 (en) Antiviral activity of the protein scytovirin and methods of use
EA200200743A1 (ru) Рекомбинантное ослабление вируса репродуктивного и респираторного синдрома свиней (prrsv)
EA200301089A1 (ru) Противовирусный агент
DE60229966D1 (de) Diabetesmodell
BR9801992A (pt) Processos para a preparação de vìrus da doença de marek usando linhas celulares contìnuas de mamìfero.
DE69533167D1 (de) Impfstoffe gegen den hepatitis b und c virus
BR9903877A (pt) Composicões e métodos para a proteção de animais contra doença associada a lentivìrus, assim como o vìrus da imunodeficiência felina
WO2003023027A3 (de) Tt-virus-sequenzen in menschlichen tumorgeweben, mittel zu deren nachweis sowie tumortherapie
DE60035680D1 (de) Komplette gensequenz des esel-leukozyten-impfstoffstammes des equinen infektiösen anemievirus und ihre anwendung
Jameel What do we know about SARS CoV-2?
Akalu et al. Broad-spectrum RNA antiviral inspired by ISG15-/-deficiency
CA2086577A1 (en) Potential target for immunotherapy to prevent replication of hiv (aids virus) in humans: cdna and protein for a putative regulator of hiv gag polyprotein expression reconstructed from the antisense strand of human p53 gene
TH64484A (th) โคลนไวรัสก่ออาการท้องร่วงในวัวจากไวรัสที่ก่อการติดเชื้อ
WO2005001096A8 (fr) Vaccins contre le sras

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1254663

Country of ref document: EP

REN Ceased due to non-payment of the annual fee